Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity
Advanced Science · 2026
DOI: 10.1002/advs.202518547 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, 2026. Verfasst von Xinru Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, Shanghai, C…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Cytokines, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Shanghai Jiao Tong University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)‐T cell immunotherapy has revolutionized the paradigm in hematological malignancies. However, its efficacy in treating solid tumors remains limited because the immunosuppressive tumor microenvironment (ITME) seriously blocks T cell activation, infiltration, and proliferation. Cytokines, driving potent assisted function by enhanced T cell expansion, persistence, and direct tumor cell killing, have long been acknowledged as promising candidates combined with CAR‐T cells to improve treatment outcomes. Despite their preclinical success, significant toxicity occurs in up to one‐third of patients induced by powerful immune‐mediated cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS). In these cases, the risk‐benefit unbalance is less advantageous for advanced cancer therapies, appealing for a profound understanding of pathophysiological mechanisms of CRS and ICANS, as well as improved management of regulating cytokine production. In this review, we first provide an overview of activation and cytotoxic mechanisms of CAR‐T cells. Second, obstacles to CAR‐T cells in the ITME are introduced in detail. Third, the advanced design of CAR‐T engineered cytokines, coupled with current research progress, is described. Furthermore, pathophysiology and clinical features of CRS and ICANS are described in detail. Lastly, prevention and/or intervention approaches of the two above‐mentioned toxicities are emphasized both for developing novel therapeutics and maximizing the benefit of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
- Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
- National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, Shanghai, China.
- College of Chemistry and Chemical Engineering, Donghua University, Shanghai, China.
ORCID-Profile: Wei-En Yuan
Förderung
- Natural Science Foundation of China
- Shanghai Jiao Tong University
- National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Aimaiti, G., Guan, Y., Sha, Y., Zhou, W., Shen, J., Zhao, B., & Yuan, W. E. (2026). Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity. Advanced Science. https://doi.org/10.1002/advs.202518547
Vancouver
Zhang X, Aimaiti G, Guan Y, Sha Y, Zhou W, Shen J, et al. Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity. Advanced Science. 2026. doi:10.1002/advs.202518547
BibTeX
@article{Zhang2026,
author = {Zhang, Xinru and Aimaiti, Gulizeba and Guan, Yuanye and Sha, Yuzhe and Zhou, Wei and Shen, Jiefeng and Zhao, Bo and Yuan, Wei-En},
title = {Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202518547}
}
EUVIMED